AbbVie stock: Oxford R&D expansion strengthens UK research footprint

Published on 11/05/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock remains in focus after the drugmaker expanded its Oxford research site. The move adds capacity across immunology, neuroscience and oncology.

Oxford expansion broadens AbbVie research

AbbVie expanded its Oxford research facility on November 4, strengthening work across immunology, neuroscience and oncology.
The project forms part of more than GBP 120 million invested and committed to UK life sciences research, collaborations and talent.
The expansion builds on AbbVie's 2022 acquisition of Oxford-based DJS Antibodies and supports future drug discovery.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie expanded its UK research and development facility in Oxford on Wednesday, November 4, adding capacity in immunology, neuroscience and oncology. The drugmaker announced the project in a company release.

Research footprint targets future medicines

The new AbbVie Oxford site covers 12,000 square feet and combines the specialist capabilities developed through AbbVie's acquisition of Oxford-founded biotechnology company DJS Antibodies in October 2022 with the broader resources of the global research network.

AbbVie said the expansion is part of more than GBP 120 million invested and committed across the UK life-sciences ecosystem. The commitment includes scientific research, academic collaborations and talent development. The company works with more than 100 universities and research organisations in the UK each year.

One collaboration with the University of Oxford is studying how patients with certain inflammatory conditions respond to treatments over an extended phase of their disease. AbbVie said the work is intended to help guide future medicine development. The company employs more than 1,100 people across its UK sites in Oxford, Maidenhead and Marlow.

Pipeline capacity remains the investor angle

For investors, the expansion points to a longer-term effort to strengthen discovery capabilities rather than an immediate product launch or earnings catalyst. The focus on immunology, neuroscience and oncology aligns the Oxford operation with three of AbbVie's core therapeutic areas and may support a broader pipeline over time.

AbbVie stock traded at 266.00 euros on Lang & Schwarz at 13:48 CET on Thursday, November 5, 2026. Investors can follow the real-time quote of AbbVie stock.